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Abstract 
Background Dairy products have been perceived as having the potential to cause adverse effects in 
individuals with Crohn’s disease (CD) and are often avoided, potentially increasing the risk of 
osteoporosis and related morbidity associated with inadequate dietary calcium intake. Objective To 
evaluate the self-reported effects of dairy products on CD symptoms and to determine whether these 
effects differed between types of dairy products consumed and disease state or location. Design 
Secondary analysis of dietary survey and clinical data from participants in the Genes and Diet in 
Inflammatory Bowel Disease study based in Auckland, New Zealand. Subjects/setting One hundred and 
sixty-five men and women diagnosed with CD for which both dietary survey data and clinical information 
were available. Statistical analyses performed 2 analysis was conducted to assess whether significant 
differences in the proportions of responses relating to a worsening of CD symptoms from individual dairy 
products were evident between individuals with active or quiescent CD, or ileal or colonic disease 
locations. Odds ratios with confidence interval were calculated to determine whether CD location was 
associated with risk of any type of adverse reaction to milk products. Logit scales were utilized to depict 
selfreported CD symptoms associated with individual dairy product consumption for ileal and colonic CD 
patients. Results Dairy products had no effect on self-reported CD symptoms for most people. Dairy 
products with a high fat content were most frequently reported to worsen perceived CD symptoms. 
Clinically, self-reported CD activity status did not influence responses to dairy products; however, colonic 
inflammation was more frequently associated with adverse CD effects in comparison to ileal CD 
involvement. Conclusions Research outcomes question the necessity of dairy product avoidance in CD 
patients and illustrate the highly individual nature of dairy product tolerance in this clinical population 
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Effects of dairy products on Crohn’s Disease symptoms are influenced by fat content 1 




















Effects of dairy products on Crohn’s Disease symptoms are influenced by fat content 20 
and disease location but not lactose content or disease activity status in a New Zealand 21 
population 22 
Background 23 
Dairy products have been perceived as having the potential to cause adverse effects in 24 
individuals with Crohn’s Disease (CD) and are thus often avoided, potentially increasing the 25 
risk of osteoporosis and related morbidity associated with inadequate dietary calcium intake.  26 
Objective 27 
To evaluate the self reported effects of dairy products on CD symptoms and to determine 28 
whether these affects differed between types of dairy products consumed and disease state or 29 
location.  30 
Design 31 
Secondary analysis of dietary survey and clinical data from participants in the ‘Genes and 32 
Diet in Inflammatory Bowel Disease’ study based in Auckland, New Zealand. 33 
Subjects/setting 34 
One hundred and sixty five men and women diagnosed with CD that had both dietary survey 35 
data and clinical information available.  36 
Statistical analyses performed 37 
Chi Squared analysis was used to assess whether significant differences in the proportions of 38 
responses relating to CD symptoms and dairy products were evident.  Odds ratios with 39 
confidence interval were calculated to determine whether CD location was associated with 40 
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the risk of adverse reactions to milk products. Logit scales were utilised for depiction of 41 
reported CD symptoms associated with individual dairy product consumption.  42 
Results 43 
Dairy products had no effect on CD symptoms for most people. The greatest proportions of 44 
adverse affects were seen for dairy products with a high fat content. Clinically, CD activity 45 
status did not influence responses to dairy products; however colonic inflammation was more 46 
frequently associated with adverse CD effects in comparison to ileal CD involvement.    47 
Conclusions 48 
Research outcomes question the necessity of dairy product avoidance in CD patients and 49 














Crohn’s Disease (CD) is a debilitating form of inflammatory bowel disease which can affect 62 
any location of the gastrointestinal tract resulting in considerable morbidity (1). The 63 
incidence of CD in a New Zealand based epidemiological study was 16.5/100,000 per year, 64 
(2), higher than in many Western Countries and thus affecting a significant proportion of the 65 
New Zealand population.  66 
Dairy products have often been perceived as having the potential to cause adverse effects in 67 
individuals with CD and are thus often avoided, potentially increasing the risk of osteoporosis 68 
and related morbidity associated with inadequate dietary calcium intake.  69 
 There are several hypotheses proposed to explain this perceived adverse affect. Perhaps the 70 
most frequently reported theory relates to the prevalence of lactose intolerance in CD 71 
patients.   A higher prevalence of lactose malabsorption as diagnosed by hydrogen breath 72 
testing, in individuals with CD has been reported in comparison to controls (3). Allergy to 73 
major milk proteins may be a further reason that a small number of CD patients report 74 
adverse affects from dairy products (4).  Additionally, individuals with CD may be 75 
susceptible to secondary lactose intolerance.  During the periods of the acute gastrointestinal 76 
inflammation characteristic of CD, quantities of the lactase, the lactose digesting enzyme, 77 
may decline in the duodenal mucosa, resulting in the gastrointestinal discomfort associated 78 
with lactose maldigestion (5). Thus disease state (active or quiescent) may affect response to 79 
dairy products in this clinical population.   80 
The disease location may further influence tolerance to dairy products in individuals with 81 
CD. As lactase is located within small intestinal villi, this is the primary site of lactose 82 
digestion (6).  Thus individuals with inflammatory disease located within this region of the 83 
gastrointestinal tract may have difficulties with lactose intolerance and thus perceive that 84 
adverse CD symptoms are associated with consumption of dairy products. 85 
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The aim of this study was to evaluate the self reported effects of dairy products on CD 86 
symptoms and to determine whether these affects differed between types of dairy products 87 
consumed, disease state or location. The identification of dairy mediated affects on CD 88 
symptoms may facilitate the provision of more targeted dietary advice on dairy products for 89 
this clinical population.  90 
Methods 91 
This study was based on a secondary analysis of dietary survey and clinical data from 165 92 
adults with CD. All subjects were Caucasian participants in the ‘Genes and Diet in 93 
Inflammatory Bowel Disease’ study based in Auckland, New Zealand (7). Subjects were 94 
selected on the basis that a complete set of dietary and clinical data was available.  95 
The ‘Genes and Diet in Inflammatory Bowel Disease’ study was approved by the New 96 
Zealand Multi-Region Human Ethics Committee (MEC/04/12/011). Access to the data for 97 
this secondary analysis met ethical approval and all information utilised was coded to protect 98 
the anonymity of participants.  99 
Clinical Data  100 
Clinical information including age, IBD diagnosis and latest Montreal classification 101 
illustrating latest CD location (8) was provided following evaluation of patient medical notes 102 
and secondary patient investigation by an experienced gastroenterologist as a part of the 103 
‘Genes and Diet in Inflammatory Bowel Disease’ study.  Individuals with a latest Montreal 104 
classification of L1, indicating ileal involvement, were grouped into the ‘ileal involvement’ 105 
group. While individuals with a classification of L2, indicating isolated colonic involvement, 106 
were classified as the ‘colonic involvement’ group.  For simplicity individuals with a 107 
classification of L3 and L4 (indicating ileocolonic and upper gastrointestinal disease in the 108 
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presence of classifications of L1-L3 respectively (9) were excluded from this part of the 109 
analysis.  110 
 Additional clinical information was sought from the dietary questionnaire whereby subjects 111 
reported current disease activity status (active or quiescent).  112 
Assessment of affects of individual dairy products 113 
For the purpose of this study dairy products were categorised to include ruminant milk 114 
(inclusive of sheep, cow and goat varieties), yoghurt, butter, custard, ice cream, cream and 115 
cheese.  116 
Self reported data on effects of dairy products were extracted from a dietary questionnaire, 117 
which required participants to nominate whether particular foods items made their IBD 118 
conditions either: ‘definitely worse’, ‘probably worse’, ‘had no effect’, ‘probably better’ or 119 
‘definitely better’. Subjects reporting that particular dairy products made their condition 120 
either ‘definitely’ or ‘probably worse’ were categorised as having an adverse reaction to that 121 
food. Similarly those reporting a ‘definitely’ or ‘probably better’ effect of a particular dairy 122 
product on their CD condition were categorised as having a beneficial effect from consuming 123 
that food. This dietary questionnaire is described in more detail elsewhere (7).  Several open 124 
ended questions within the dietary questionnaire were also analysed to determine qualitative 125 
information regarding perceived effects on CD condition associated with particular dairy 126 
products. These questions included: 127 
• Is there a difference with the type of cheese eaten? If so, please outline: 128 
• Is there a difference with the type of yoghurt eaten? If so, please outline: 129 
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Both quantitative and qualitative information about the frequency and nature of adverse 130 
reactions to milk products was extracted from this supplementary questionnaire following an 131 
analysis of open ended questions including: 132 
• Have you ever had an adverse reaction to a milk product? 133 
• What were your adverse symptoms after consuming milk products? 134 
• Have you seen a health professional about your reactions to milk products (if 135 
applicable)? 136 
• Have you been formally diagnosed with an intolerance or allergy? 137 
Data Analysis  138 
Qualitative data (including reports on symptoms of adverse reactions to dairy products and of 139 
symptomatic differences from different types of dairy products consumed) was categorised 140 
accordingly and the proportion of individuals responding to each category was calculated. 141 
Chi Squared analysis was conducted to assess whether significant differences in the 142 
proportions of responses relating to CD symptoms and dairy products were evident.  Odds 143 
ratios with confidence interval were calculated to determine whether CD location was 144 
associated with the risk of adverse reactions to milk products.  Results were considered 145 
statistically significant at p <0.05. 146 
For interpretation of data grouped by disease location (ileal vs. colonic), logit scales were 147 
utilised to create a clear visual representation of reported CD symptoms associated with 148 
consumption of individual dairy products whilst addressing the issue of the variance of 149 
proportions between the groups.  150 
All analyses were conducted using SPSS (V15.0 1989-2006, SPSS Inc., Chicago II, USA), R 151 
(R Development Core Team (2009). R: A language and environment for 152 
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  Statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-153 
900051-07-0, URL http://www.R-project.org.ref) and SAS (V9.1 SAS Institute., Cary, NC, 154 
USA) statistical software packages.  155 
Results 156 
Dietary and clinical data was available for 165 patients with CD, (mean age 48.8±16.3).The 157 
study sample was predominantly female, (males n=49, mean age 50.6±17.8), females n= 116 158 
(mean age 48.0±15.6).  159 
Clinical Profiles 160 
Of the study sample, 80 patients (48.5%) reported that their CD was currently active and 82 161 
(49.7%) identified their CD as being in the quiescent phase. Three patients did not answer 162 
this survey question. There was no difference between the sexes in the proportion reporting 163 
an active CD period at the time of survey completion (χ
2
 = 0.38, p= 0.54). 164 
 Data was available for 160 patients on the latest Montreal classifications indicating the 165 
location of CD. Isolated ileal disease involvement was present for 32.7% of the study sample, 166 
while 27.9% displayed evidence of isolated colonic involvement (Table 1).   167 
There was no significant difference between males and females in terms of CD location (χ
2
 = 168 
0.98, p= 0.81).  169 
Effects of Dairy products on CD symptoms 170 
 Forty two participants (25.5%) reported having an adverse reaction to a product containing 171 
milk, whilst 111 (67.3%) felt that they had no experience of an adverse event with milk 172 
product consumption. Of patients reporting an adverse reaction associated with a milk 173 
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product, 24 (61.5%) of those reported that the reaction was persistent, while 7 individuals 174 
(4.2%) felt that it was an isolated event.  175 
A formal diagnosis of lactose intolerance was reported for 11 patients (6.7% of the study 176 
population).  A total of 41 CD patients described adverse symptoms experienced following 177 
consumption of milk products (Figure 1).  178 
As an aside to this data, naturopaths were the listed as the health practitioner most frequently 179 
sought for advice regarding adverse affects to dairy products  (n=9), specialist consultants 180 
including gastroenterologists and allergy specialists were the next most frequently sought 181 
(n=8), followed by general practitioners (n=7). Only one individual reported seeking advice 182 
in relation to dairy product intolerance from a dietitian.  183 
Reported associations between dairy product consumption and CD symptoms 184 
No effect on CD symptoms was reportedly associated with consumption of butter, standard 185 
cow’s milk and reduced fat cow’s milk in 71.5%, 64.2% and 58.2% of all patients 186 
respectively. Dairy products most frequently reported as associated with worsening CD 187 
symptoms were cream (43.6%), ice cream (37.6%) and cheese (34.5%). Conversely, yoghurt, 188 
the dairy product most frequently perceived as beneficial was reported by 14.5% of 189 
individuals as having favourable effects on CD symptoms.  The response to this question was 190 
quite varied (Table 2). 191 
Cheese 192 
When asked whether the type of cheese may influence CD symptoms, 26.1% of participants 193 
reported positively. The flavour strength of the cheese was most frequently reported as 194 
influencing tolerance, with 15 patients reporting that increased strength cheese decreased 195 
tolerance. Richer/soft cheeses were reported to increase adverse affects for 9 patients, with a 196 
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preference for Feta and Edam cheese varieties reported by 8 and 7 patients respectively. 197 
Cheeses with a lower fat content were reported to increase tolerance (n= 6) as did hard 198 
cheeses (n=5) and plain cheeses without added herbs (n= 3). Melted cheese was associated 199 
with an increase in adverse effects for 4 CD patients.  200 
Yoghurt 201 
 In total 23.0% of respondents reported that the type of yoghurt consumed may also be a key 202 
factor relating to whether it would be tolerated.  Patients reported that yoghurts containing 203 
live cultures such as acidophilus were most beneficial to CD symptoms (n=19), whilst natural 204 
yoghurt was preferable to sweetened alternatives for 11 patients. A preference for reduced fat 205 
yoghurt was reported (n=9), with yoghurt lacking seeds or fruit preferred by a further 4.8% 206 
(n=8) of individuals.  207 
Disease Activity and effect of dairy products on CD symptoms 208 
 There were no significant differences in the proportion of dairy product mediated CD 209 
symptoms between patients in the active or quiescent CD state (Table 3).  210 
Site of Disease and effect of dairy products on CD symptoms 211 
Likewise, no significant differences were detected between CD symptoms from individual 212 
dairy products and ileal or colonic disease location (data not shown). However, significantly 213 
more patients with colonic disease activity reported ever having an adverse reaction to dairy 214 
products compared to those with ileal disease (χ
2 
=5.90, p= 0.015), (OR = 0.32, 95% CI = 215 
(0.13-0.82), p = 0.017)).  216 
Logit scales of adverse and beneficial CD effects from individual dairy products in 217 
individuals with either small intestinal (ileal) or colonic CD involvement are displayed in 218 
figures 2(a) and (b). Only dairy products with at least one reported beneficial/ adverse effect 219 
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on CD symptoms can be plotted with the Logit scale.  Thus for patients with ileal 220 
involvement butter, Goat and Sheep milk were not included in the Logit graph. Similarly, 221 




The analysis of self reported effects of consuming dairy products on CD symptoms has 226 
clearly illustrated the extent of variation in tolerance to dairy products within this clinical 227 
population.  228 
Most importantly, the majority of the study sample reported that consumption of dairy 229 
products made no difference to CD symptoms. This finding reinforces the need to determine 230 
tolerance to dairy products in CD patients prior to encouraging widespread avoidance of this 231 
food group, an idea that may be still encouraged by some physicians and many alternative 232 
health consultants. Whilst it may be pertinent to avoid some dairy products for CD patients 233 
with congenital hypolactasia or during periods of active disease, unnecessary avoidance of all 234 
dairy products by this clinical group without appropriate nutrition support may have 235 
deleterious consequences.  Individuals with CD are more susceptible to osteoporosis (10). 236 
Prolonged corticosteroid utilisation to induce remission of inflammation has been 237 
demonstrated to reduce bone mineral density (BMD) in CD patients (11). CD itself may be an 238 
independent risk factor for osteoporosis (12) with an increase in pro- inflammatory cytokines 239 
associated with disease pathogenesis mediating excessive bone resorption (13). According to 240 
the National New Zealand Nutrition Survey (14) milk, cheese and other dairy products were 241 
the highest food contributors of dietary calcium in the New Zealand population, contributing 242 
37%, 11% and 5% of total calcium consumed respectively.  While evidence is conflicting, 243 
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Abitbol and colleagues (15) demonstrated a protective effect of calcium intake on BMD in 244 
individuals with inflammatory bowel disease, and increased dairy products consumption has 245 
been reported to retard bone loss (16).  Thus, eliminating dairy products as the highest 246 
contributor of dietary calcium from the diet may further exacerbate risk of osteoporosis and 247 
related morbidity in individuals with CD in New Zealand.  248 
Intermittent secondary lactose intolerance may be experienced by some individuals with CD 249 
during periods of active gastrointestinal inflammation (5).  Formally diagnosed lactose 250 
intolerance was reported for only a small proportion of the study sample. However, in our 251 
study, symptoms consistent with lactose maldigestion, including bloating, diarrhoea and gas 252 
(17), were the most frequently reported adverse effect associated with milk product 253 
consumption. This finding indicates that secondary lactose intolerance may have influenced 254 
the response to dairy products for a greater number of this CD study sample.  255 
Seeking assistance from alternative health practitioners is a practice frequently observed in 256 
individuals suffering from inflammatory bowel conditions (18).  Advice of this nature is often 257 
sought as an adjunct to conventional medical therapies in an effort to establish a sense of 258 
control over this debilitating condition (19). This practice was evident in our clinical 259 
population whereby naturopaths were the most frequently utilised source of advice regarding 260 
issues with dairy product tolerance. Ensuring accurate advice in relation to dairy product 261 
consumption is imperative to prevent micronutrient deficiencies in this clinical population.  262 
Appropriate dietetic intervention is instrumental to ensuring optimal BMD in patients with 263 
CD (20).  Thus, for individuals reporting adverse CD effects associated with dairy products, 264 
dietetic intervention should be encouraged as part of the continuum of care.  265 
 In our study sample, tolerance for individual dairy product tolerance was highly variable. In 266 
fact, the majority of individuals experienced no effect on CD symptoms associated with each 267 
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of the individual dairy products under question. An exception to this finding was evident for 268 
cream, with the highest proportion of individuals in the study sample reporting adverse CD 269 
symptoms associated with its consumption. The perceived adverse affects may relate to the 270 
high fat content of this item.  High dietary fat intakes decrease gastric emptying rates (21). In 271 
addition, disorders in gastrointestinal motility have been observed in this clinical population, 272 
with affected individuals more likely to experience gastric hypomotility than controls (22).  273 
Thus effects of dietary-fat mediated gastroparesis following consumption of dairy products 274 
rich in fat may be more pronounced in individuals with CD.  Symptoms of gastroparesis 275 
include nausea; abdominal pain and bloating (23) all of which were frequently reported as 276 
adverse affects following dairy product consumption in our study.   277 
Other dairy products containing higher amounts of fat including ice cream, cheese and 278 
standard cow’s milk were associated with larger proportions of worsening CD symptoms in 279 
comparison to lower fat dairy counterparts. Furthermore, reduced fat cheese and yoghurt 280 
varieties were perceived as more tolerable.  These findings illustrate that the fat content of 281 
dairy products may be a key factor influencing tolerance in this clinical population.   282 
Of interest we found, that butter, a dairy product that contains a very high proportion of fat, 283 
was not reported as having adverse effects on CD symptoms for the majority of individuals. It 284 
may be that butter is not being consumed in amounts great enough to influence gastric stasis 285 
in the study sample.  Conversely, butter contains a relatively high proportion of conjugated 286 
linoleic acid (CLA). CLA has been implicated in the amelioration of inflammation in 287 
experimental models of IBD, particularly in relation to colitis (24). Thus the lack of adverse 288 
effects on CD symptoms associated with butter consumption may be the result of this CLA 289 
mediated anti-inflammatory effect.  290 
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Probiotic –containing yoghurt has been demonstrated to attenuate markers of inflammation in 291 
individuals with inflammatory bowel disease (25) and the dairy product most frequently 292 
associated with having a beneficial effect on CD symptoms in our study was yoghurt.  293 
However, we found yoghurt to also be associated with a worsening of CD symptoms for a 294 
slightly greater proportion of individuals than had experienced beneficial effects from it.  A 295 
limitation of the survey which we utilised for analysis was that it failed to distinguish 296 
between CD effects experienced from probiotic yoghurt and non-probiotic varieties.  An 297 
analysis of qualitative responses indicated that for individuals experiencing   a difference in 298 
CD symptoms dependent on the type of yoghurt consumed, those containing live cultures and 299 
probiotics were most frequently associated with beneficial effects.  Thus probiotic yoghurts 300 
appeared to benefit individuals with CD in preference to yoghurt without live cultures; 301 
however this is an area that requires further research.  302 
It was expected from previous observations (7) that goat and sheep milk may result in less 303 
adverse CD effects than their bovine counterparts. Goat milk in particular contains 304 
oligosaccharides which have demonstrated anti-inflammatory effects in rat models of 305 
inflammatory bowel disease (26). In addition sheep and goat’s milk contain higher 306 
proportions of medium chain triglycerides than cow’s milk which may enhance digestibility 307 
(27). Finally, like butter, sheep milk contains relatively high amounts of CLA (28) which 308 
may further ameliorate gastrointestinal inflammation (24). In our study, only a very small 309 
proportion of individuals reported a beneficial CD effect associated with consumption of 310 
these milk products, with a slightly greater proportion reporting adverse affects. However, 311 
because the majority of individuals did not answer this question, indicating that they did not 312 
consume these items, it was not possible to determine the true effect of goat and sheep milk 313 
on CD symptoms.  Given emerging evidence to suggest a potentially beneficial role for sheep 314 
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and goat milks in relation to CD symptoms, evaluating the true effects of these products may 315 
be an important area for future research.  316 
The lactose content of the individual dairy products did not seem to influence CD symptoms 317 
in our study sample. Cow’s milk, which contains a significantly greater amount of lactose per 318 
serve than cream, ice cream or cheese (17) was associated with comparatively less symptom 319 
worsening.  Additionally, lactose tolerance may be influenced by gastrointestinal transit time, 320 
with higher fat milk products travelling less rapidly throughout the small intestine, affording 321 
lactase a greater opportunity for lactose digestion (17). Thus, if lactose was a key factor 322 
relating to CD symptoms in our study sample, reduced fat cow’s milk would have been 323 
associated with less favourable CD effects than its standard variety. As this was not the case 324 
it appears that the lactose content of individual dairy products does not have a major impact 325 
on CD symptoms.  In contrast, qualitative responses regarding the types of cheese and 326 
yoghurt consumed that may affect tolerance indicate a lactose effect in a small proportion of 327 
the study sample.  The preference for yoghurt containing live bacteria previously outlined 328 
may be associated with tolerance to lactose for some individuals, given that these organisms 329 
perform the activity of lactase (29), enhancing digestibility. Similarly several individuals 330 
reported a preference for hard cheeses such as cheddar in comparison to soft cheeses. Hard 331 
cheeses may contain slightly less lactose than soft varieties such as cream cheese (17) and 332 
may thus be better tolerated by individuals with lactose digestion issues.                  333 
 In our study disease activity (active vs. quiescent) did not appear to influence perceived 334 
effects of dairy products on CD symptoms, with a similar proportion of individuals reporting 335 
either adverse or beneficial dairy mediated CD effects irrespective of disease activity. This 336 
finding challenges the necessity of dairy avoidance during active CD.  However, as disease 337 
activity was subjectively reported, these findings should be interpreted with caution.   338 
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Reference to the logit scales developed in our analysis shows that individuals with isolated 339 
colonic inflammation appeared to have an increase in adverse CD symptoms from consuming 340 
reduced fat cow’s milk, custard, sheep’s milk and yoghurt was evident in the logit scales in 341 
comparison to those with isolated small intestinal (ileal) involvement. This was an 342 
unexpected finding as it was anticipated that individuals with small intestinal inflammation 343 
would be more likely to have issues with lactose and thus dairy product tolerance, given that 344 
lactase lines the small intestinal mucosa (6).  Furthermore Annese et al (22) reported most 345 
severe gastrointestinal motility disorders occur in Crohn’s ileitis. This unexpected finding 346 
warrants further investigation and may relate to functional differences in gut microbiota 347 
amongst individuals with CD affecting varied locations throughout the gastrointestinal tract.   348 
A possible explanation for the unexpected outcomes observed in relation to dairy product 349 
tolerance in this study may be attributable to individual genetic variation. Although clear 350 
genomic loci such as NOD2 and IL23R have been repeatedly associated with this CD in 351 
genome wide association studies (30), there is a paucity of evidence in relation to genetic 352 
factors that may influence tolerance to dairy products in individuals with this inflammatory 353 
condition.  Future research efforts should consider the impact of genetic interactions on dairy 354 
product tolerance in CD to conclusively address the research question.  355 
This study is limited by the subjective nature of the dietary questionnaire utilised, and the 356 
relatively small size of the CD sample that make it difficult to extrapolate findings to the 357 
wider Crohn’s disease community. However, to our knowledge, this is the first study to 358 
assess the perceived affects of dairy products on CD symptoms taking into account both 359 






In conclusion, within our study sample of CD patients in Auckland, New Zealand, dairy 364 
products in general had no effect on CD symptoms for most people. When analysed 365 
according to type of dairy product, the greatest proportion of adverse affects were seen for 366 
products with a high fat content.  The lactose content of individual dairy products did not 367 
influence perceived affects on CD symptoms for the majority of patients. Clinically, CD 368 
activity status did not influence responses to dairy products; however site of disease appeared 369 
to have an effect. Colonic inflammation was more frequently associated with an increase in 370 
reported adverse CD effects from dairy product consumption in comparison to ileal CD 371 
involvement.   Results from this exploratory study reinforce the idea that that ‘one size does 372 
not fit all’ when it comes to making dietary recommendations relating to dairy product 373 
consumption for individuals with Crohn’s Disease.  Future research should consider the 374 
identification of genetic variants that may further explain tolerance to dairy products in this 375 
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Table 1.  Latest subject Montreal classifications for location of CD (n=160) 







n (%)  

























Figure 1. Adverse symptoms reported by CD patients following consumption of dairy products (n=41)* 
*Some patients reported more than 1 symptom.  Other adverse symptoms reported include: asthma (n=1), reflux (n=1), bowel irritation (n=1) 



























Table 2. Self-reported effect of individual dairy products on CD symptoms (n=165) 
Food Item CD 
Symptoms 
Worse 











Standard Cow’s Milk  51 (30.9%)  91 (55.2% ) 2 (1.2%)   21 (12.7%) 
Reduced Fat Cow’s 
Milk 
 30 (18.2%) 96 (58.2%) 10 (6.0%) 29 (17.6%) 
Butter 29 (17.6%) 118 (71.5%) 2 (1.2%)  16 (9.7%) 
Custard 32 (19.4%) 106 (64.2%) 8 (4.8%) 19 (11.5%) 
Goat’s Milk 11 (6.7%) 27 (16.4%) 4 (2.4%) 123 (74.5%) 
Sheep’s Milk 11 (6.7%) 27 (16.4%) 5(3.0%) 122 (73.9%) 
Ice Cream 62 (37.6%) 94 (57.0%) 3 (1.8%)  6 (3.6%) 
Yoghurt 31 (18.8%) 94 (57.0%) 24 (14.5%) 16 (9.7%) 
Cheese  57 (34.5%) 95 (57.6%) 5 (3.0%) 8 (4.8%) 
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Table 3. Self-reported effect of individual dairy products on worsening CD symptoms analyzed by disease activity status (n=162) 
Food Item CD Symptoms 
Worse  
n (%) 
No difference to 















Chi Squared Analysis 
Standard Cow’s 
Milk 
21  30  45  43  (χ
2
= 1.28,  p= 0.26) 
Reduced Fat 
Cow’s Milk 
14  15  
 
46  48  (χ
2 
= 0.004, p = 0.95) 
Butter 15 9  57  61  (χ
2
= 1.61, p= 0.20) 
Custard 17  14 50  54  (χ
2
 = 0.48, p= 0.51) 
Goat’s Milk 7  4  13  13  (χ
2
= 0.58, p= 0.45) 
Sheep’s Milk 5  6  13  13  (χ
2 
= 0.64, p= 0.80) 
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Ice Cream 31  30  45 47  (χ
2 
= 0.053, p= 0.82) 
Yoghurt 16   14  46  47  (χ
2 
= 0.14, p= 0.71) 
Cheese 27  29  46   47 (χ
2
= 0.02, p= 0.883) 
Cream 36   36 35  35  (χ
2  
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